zopapogene imadenovec-drba (Papzimeos)

Indications

• non-replicating adenoviral vector-based immunotherapy indicated for treatment of adults with recurrent respiratory papillomatosis

Dosage

• 510E11 particle units (PU) per injection administered by subcutaneous injection 4 times over a 12-week interval.
• single-dose vial that contains 510E11 particle units in an extractable volume of 1 mL of suspension

Adverse effects

• common (>= 5%)
  • injection site reactions, fatigue, chills, pyrexia, myalgia, nausea
• thrombotic events may occur following administration of adenoviral vector-based therapies

Mechanism of action

• immunotherapy designed to generate an immune response directed against HPV6 & HPV11 proteins in patients with recurrent respiratory papillomatosis
• designed to express afusion antigen of selected regions of HPV6 & HPV11

More general terms

• Immunotherapy